Overall survival and histology‐specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma

BACKGROUND: We performed a randomized phase 3 study of trabectedin versus dacarbazine in previously‐treated patients with liposarcoma/leiomyosarcoma (LPS/LMS). METHODS: Patients were randomized 2:1 to trabectedin (n = 384) or dacarbazine (n = 193) administered intravenously every 3 weeks. The primar...

全面介紹

Na minha lista:
書目詳細資料
發表在:Cancer
Main Authors: Patel, Shreyaskumar, von Mehren, Margaret, Reed, Damon R., Kaiser, Pamela, Charlson, John, Ryan, Christopher W., Rushing, Daniel, Livingston, Michael, Singh, Arun, Seth, Rahul, Forscher, Charles, D'Amato, Gina, Chawla, Sant P., McCarthy, Sharon, Wang, George, Parekh, Trilok, Knoblauch, Roland, Hensley, Martee L., Maki, Robert G., Demetri, George D.
格式: Artigo
語言:Inglês
出版: John Wiley and Sons Inc. 2019
主題:
Original Articles
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6771856/
https://ncbi.nlm.nih.gov/pubmed/31173362
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.32117
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍